Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

InterCure Ltd. (INCR) vs Talphera, Inc. (TLPH)

InterCure Ltd. and Talphera, Inc. are both Drug Manufacturers Specialty & Generic companies. InterCure Ltd. and Talphera, Inc. are of similar size ($62.3M and $60.7M). Talphera, Inc. has negative trailing earnings, so its P/E is not meaningful; InterCure Ltd. trades at 9.8×. InterCure Ltd. grew revenue faster over the last twelve months: 16.2% against −73.1%. InterCure Ltd. has the higher net margin (4.88% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, InterCure Ltd. leads on 12 and Talphera, Inc. on 3.

Valuation

Metric INCR TLPH Drug Manufacturers Specialty & Generic median
P/E 9.84 n/m 20.14
P/S 1.98 209.21 2.25
P/B 1.96 6.19 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA 23.47 n/m 12.29
EV/Sales 2.12 183.86 2.56
Earnings yield 10.16% (22.88%) (2.99%)
Free cash flow yield (0.34%) (10.82%) 0.00%

Profitability

Metric INCR TLPH Drug Manufacturers Specialty & Generic median
Gross margin 32.74% 100.00% 53.94%
Operating margin 0.00% 0.00% 0.00%
Net margin 4.88% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (143.36%) (0.40%)
Return on assets 0.00% (69.60%) (3.32%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric INCR TLPH Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 16.15% (73.07%) 10.01%
EPS growth (last fiscal year) 52.50% 32.00% —
Revenue growth, 5-year CAGR 31.11% (58.55%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INCR TLPH Drug Manufacturers Specialty & Generic median
Debt to equity 0.27 0.00 0.05
Current ratio 1.85 4.29 2.31
Net debt to EBITDA (4.07) 1.50 0.85

Dividend

Metric INCR TLPH Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric INCR TLPH Drug Manufacturers Specialty & Generic median
Market cap 62.33m 60.73m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack